DSpace DSpace Softwareについて English
 

GINMU >
01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2024年度 >

このアイテムの引用には次の識別子を使用してください: http://hdl.handle.net/10564/4461

タイトル: Prediction of Efficacy for Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma with Hepatobiliary-Phase Gadolinium Ethoxybenzyl Diethylenetriaminepentaacetic Acid MRI
その他のタイトル: EOB造影MRIの肝細胞相を用いた切除不能肝細胞癌に対するアテゾリズマブ+ベバシズマ ブ併用療法の治療効果予測
著者: Kunichika, Hideki
Minamiguchi, Kiyoyuki
Tachiiri, Tetsuya
Shimizu, Kozo
Taiji, Ryosuke
Yamada, Aya
Nakano, Ryota
Irizato, Mariko
Yamauchi, Satoshi
Marugami, Aki
Marugami, Nagaaki
Kishida, Hayato
Nakagawa, Hiroyuki
Takewa, Megumi
Kageyama, Ken
Yamamoto, Akira
Ueshima, Eisuke
Sofue, Keitaro
Kita, Ryuichi
Kurakami, Hiroyuki
Tanaka, Toshihiro
キーワード: hepatocellular carcinoma
atezolizumab plus bevacizumab
magnetic resonance imaging
hepatobiliary phase
coefficient of variation
発行日: 2024年6月
出版者: MDPI
引用: Cancers. 2024 Jun, vol.16, no.12, article no.2275
抄録: Background: This study aimed to examine whether the coefficient of variation (CV) in the hepatobiliary-phase (HBP) of Gd-EOB-DTPA-MRI could be an independent predictive factor for tumor progression. Methods: Patients who underwent Gd-EOB-DTPA-MRI before Atezolizumab/ bevacizumab therapy at six affiliated institutions between 2018 and 2022 were included. CV for each patient was calculated as the mean value for up to five tumors larger than 10 mm, and CV of the whole tumor was calculated using LIFEx software. The tumor response was evaluated within 6–10 weeks. The primary endpoint was to investigate the predictive factors, including CV, related to tumor progression using logistic regression analysis. The secondary endpoints were tumor response rate and progression-free survival (PFS) based on CV. Results: Of the 46 enrolled patients, 13 (28.3%) underwent early progressive disease. Multivariate analysis revealed that a high CV (≥0.22) was an independent predictive factor for tumor progression (p = 0.043). Patients with a high CV had significantly frequent PD than those with a low CV (43.5 vs. 13.0%, p = 0.047). Patients with a high CV tended to have shorter PFS than those with a low CV (3.5 vs. 6.7 months, p = 0.071). Conclusion: Quantitative analysis using CV in the HBP of Gd-EOB-DTPA-MRI may be useful for predicting tumor progression for atezolizumab/bevacizumab therapy.
内容記述: 権利情報:© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
URI: http://hdl.handle.net/10564/4461
ISSN: 2072-6694
DOI: https://doi.org/10.3390/cancers16122275
学位授与番号: 24601甲第966号
学位授与年月日: 2025-03-14
学位名: 博士(医学)
学位授与機関: 奈良県立医科大学
出現コレクション:2024年度

このアイテムのファイル:

ファイル 記述 サイズフォーマット
02甲966本文の要旨.pdf02甲966本文の要旨124.24 kBAdobe PDF見る/開く
03甲966審査要旨.pdf03甲966審査要旨124.89 kBAdobe PDF見る/開く

このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。

 

Valid XHTML 1.0! Powered by DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - ご意見をお寄せください